Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047411 | 0.92 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2HRH3HTR6 | |
| SCHEMBL3061625 | 0.92 | HRH3 (0.36) | MEN1KMT2ASMN1; SMN2HRH3HTR6 | |
| SCHEMBL3050853 | 0.90 | HSPB1 (0.32) | MEN1KMT2ASMN1; SMN2HRH3HTR6 | |
| SCHEMBL3051214 | 0.88 | HRH3 (0.35) | SMN1; SMN2HRH3HTR6ALDH1A1 | |
| SCHEMBL3057195 | 0.87 | HTR2C (0.32) | EGLN1 | |
| SCHEMBL3065126 | 0.85 | GAA (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3060418 | 0.84 | HTR2C (0.36) | MEN1KMT2ASMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL3058665 | 0.77 | OPRM1 (0.38) | HRH3DRD4ALDH1A1 | |
| SCHEMBL3051012 | 0.76 | L3MBTL1 (0.36) | MEN1KMT2A | |
| SCHEMBL3056040 | 0.75 | LOXL2 (0.43) | MEN1KMT2ASMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | EGLN1 254/4885MEN1 275/4885KMT2A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.